Additional file 14 of Imipramine and olanzapine block apoE4-catalyzed polymerization of Aβ and show evidence of improving Alzheimer’s disease cognition

Additional file 14. Summary statistics of NACC data analyses. (A, B) Subject information for MMSE models comparing (A) imipramine and other antidepressants or (B) olanzapine and other antipsychotics, including age, sex, baseline MMSE score, and drug exposure time. (C, D) Subject information for clinical diagnosis reversion models comparing (C) imipramine and other antidepressants or (D) olanzapine and other antipsychotics, including age, sex, baseline MMSE score, drug exposure time, number of subjects with reversions, and number of reversions per subject. (E, F) Subject information for clinical diagnosis conversion models comparing (E) imipramine and other antidepressants or (F) olanzapine and other antipsychotics, including age, sex, baseline MMSE score, drug exposure time, number of subjects with conversions, and number of conversions per subject. (G, H) Subject information for multiple medications models comparing (G) imipramine, doxepin, fluoxetine, citalopram, and all other antidepressants or (H) olanzapine, aripiprazole, quetiapine, and all other antipsychotics, including age, sex, baseline MMSE score, drug exposure time, number of subjects with reversions, and number of reversions per subject. (I) Complete test statistics and degrees of freedom for all statistical tests.